{"id":337604,"date":"2026-08-13T17:30:25","date_gmt":"2026-08-13T17:30:25","guid":{"rendered":"https:\/\/www.europesays.com\/se\/337604\/"},"modified":"2026-08-13T17:30:25","modified_gmt":"2026-08-13T17:30:25","slug":"novo-nordisk-forsvarar-stamning-mot-eli-lilly-cnbc","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/se\/337604\/","title":{"rendered":"Novo Nordisk f\u00f6rsvarar st\u00e4mning mot Eli Lilly &#8211; CNBC"},"content":{"rendered":"<p class=\"font-sans text-base text-text-main dark:text-text-main-dark font-normal leading-[1.4]\">Danska l\u00e4kemedelsbolaget Novo Nordisks vd Mike Doustdar f\u00f6rsvarar bolagets st\u00e4mning mot Eli Lilly och anser att rivalens marknadsf\u00f6ring av viktminskningsl\u00e4kemedlet Zepbound inte ger patienter hela bilden. Det sade Doustdar i en intervju med CNBC:s program &#8221;Mad Money&#8221;.\n <\/p>\n<p>Novo Nordisk menar att Lillys j\u00e4mf\u00f6relser bygger p\u00e5 en \u00e4ldre och l\u00e4gre dos av Wegovy och inte tar h\u00e4nsyn till den nyare dosen p\u00e5 7,2 milligram. Eli Lilly avvisar kritiken och framh\u00e5ller att dess reklam bygger p\u00e5 en direkt j\u00e4mf\u00f6rande klinisk studie.\n <\/p>\n<p>Sedan st\u00e4mningen l\u00e4mnades in har Novo Nordisks aktie fallit 6 procent, medan Eli Lilly har stigit n\u00e4stan 4 procent.<br \/>\n <br class=\"col-start-2\"\/><\/p>\n<p class=\"font-sans text-base text-text-main dark:text-text-main-dark font-normal leading-[1.4]\">Samuel Alaei<br \/>\n <br class=\"col-start-2\"\/><br \/>\n Nyhetsbyr\u00e5n Finwire<\/p>\n","protected":false},"excerpt":{"rendered":"Danska l\u00e4kemedelsbolaget Novo Nordisks vd Mike Doustdar f\u00f6rsvarar bolagets st\u00e4mning mot Eli Lilly och anser att rivalens marknadsf\u00f6ring&hellip;\n","protected":false},"author":2,"featured_media":337605,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[65],"tags":[72,70,71,6631,6456,6457,34,31,33,32,30],"class_list":["post-337604","post","type-post","status-publish","format-standard","has-post-thumbnail","category-ekonomi","tag-business","tag-economy","tag-ekonomi","tag-eli-lilly","tag-novo-nordisk-adr","tag-novo-nordisk-b","tag-se","tag-svenska","tag-sverige","tag-sweden","tag-swedish"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@se\/117089391419078682","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/posts\/337604","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/comments?post=337604"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/posts\/337604\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/media\/337605"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/media?parent=337604"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/categories?post=337604"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/tags?post=337604"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}